Trial Profile
Effects of sorafenib on the modulation of soluble angiogenesis factors in patients with unresectable hepatocellular carcinoma [EFECTO DE SORAFENIB SOBRE LA MODULACION DE LOS FACTORES SOLUBLES ANGIOGIOGENICOS EN PACIENTES CON CARCINOMA HEPATOCELULAR IRRESECABLE]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2011
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 29 Aug 2011 New trial record